Market Closed -
Nasdaq
04:00:01 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
0.7668
USD
|
-4.15%
|
|
-8.54%
|
-73.83%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
564.3
|
104.6
|
25.86
|
119.3
|
31.68
|
-
|
-
|
Enterprise Value (EV)
1 |
411.7
|
20.55
|
-48.31
|
119.3
|
-12.42
|
-57.82
|
-100.5
|
P/E ratio
|
-4.93
x
|
-2.46
x
|
-0.56
x
|
-2.36
x
|
-0.63
x
|
-0.77
x
|
-0.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
11.8
x
|
4.76
x
|
19
x
|
13.8
x
|
EV / Revenue
|
-
|
-
|
-
|
11.8
x
|
-1.87
x
|
-34.6
x
|
-43.7
x
|
EV / EBITDA
|
-14,011,550
x
|
-489,413
x
|
1,023,258
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-14,918,977
x
|
-571,431
x
|
1,158,691
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
0.94
x
|
-0.17
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,214
|
23,463
|
23,560
|
40,711
|
41,153
|
-
|
-
|
Reference price
2 |
24.31
|
4.460
|
1.097
|
2.930
|
0.7699
|
0.7699
|
0.7699
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10.09
|
6.65
|
1.671
|
2.3
|
EBITDA
|
-29.38
|
-42
|
-47.21
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.42
|
-42.07
|
-47.28
|
-51.99
|
-50.56
|
-59.59
|
-70.91
|
Operating Margin
|
-
|
-
|
-
|
-515.34%
|
-760.23%
|
-3,565.21%
|
-3,083.01%
|
Earnings before Tax (EBT)
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-49.98
|
-56.31
|
-73.77
|
Net income
1 |
-29.54
|
-42.29
|
-46.18
|
-47.92
|
-50.67
|
-56.95
|
-70.98
|
Net margin
|
-
|
-
|
-
|
-474.96%
|
-761.86%
|
-3,407.08%
|
-3,086%
|
EPS
2 |
-4.930
|
-1.810
|
-1.960
|
-1.240
|
-1.225
|
-1.003
|
-0.9775
|
Free Cash Flow
|
-27.59
|
-35.97
|
-41.69
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.964
|
2.165
|
3.073
|
2.887
|
2.002
|
1.795
|
1.895
|
1.259
|
0.65
|
0.65
|
EBITDA
|
-9.115
|
-
|
-11.87
|
-11.54
|
-12.09
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.135
|
-11.73
|
-11.88
|
-11.56
|
-12.11
|
-13.2
|
-13.97
|
-13.66
|
-11.16
|
-12.63
|
-12.7
|
-12.58
|
-15.37
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-672.05%
|
-645.36%
|
-444.45%
|
-386.7%
|
-631.02%
|
-707.71%
|
-663.99%
|
-1,220.94%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-13.99
|
-13.08
|
-12.17
|
-
|
-
|
Net income
1 |
-9.184
|
-11.76
|
-11.87
|
-11.4
|
-11.14
|
-12.79
|
-12.82
|
-12.35
|
-9.95
|
-11.62
|
-13.7
|
-13.42
|
-11.93
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-651.27%
|
-592.33%
|
-402.02%
|
-344.65%
|
-580.67%
|
-762.95%
|
-707.92%
|
-947.62%
|
-
|
-
|
EPS
2 |
-0.3900
|
-0.5000
|
-0.5100
|
-0.4800
|
-0.4700
|
-0.4000
|
-0.3200
|
-0.3000
|
-0.2300
|
-0.2800
|
-0.3333
|
-0.3300
|
-0.3033
|
-0.2500
|
-0.2350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/16/23
|
5/15/23
|
8/14/23
|
11/13/23
|
3/13/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
153
|
84.1
|
74.2
|
-
|
44.1
|
89.5
|
132
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.6
|
-36
|
-41.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
4.740
|
-6.350
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-4.590
|
-1.540
|
-1.770
|
-
|
-
|
-
|
-
|
Capex
|
0.07
|
0.09
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/21
|
3/14/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
0.7699
USD Average target price
2.75
USD Spread / Average Target +257.19% Consensus |
1st Jan change
|
Capi.
|
---|
| -73.83% | 31.68M | | +33.37% | 50.85B | | +1.55% | 42.82B | | +49.11% | 42.03B | | -4.22% | 29.55B | | +11.57% | 26.11B | | -21.00% | 19.13B | | +7.36% | 13.05B | | +28.30% | 12.16B | | +23.80% | 12.08B |
Other Biotechnology & Medical Research
|